Related Experiment Videos
12-O-tetradecanoylphorbol-13-acetate (TPA) downregulates expression of CD30 in erythroleukemia cell line K562
1First Department of Pathology, School of Medicine, Chiba University, Japan.
Abstract:
CD30, a member of the tumour necrosis factor/nerve growth factor receptor superfamily, has been thought to have pleiotropic functions on immune response. However, there has been only a little information about the mechanism of CD30 expression. In this study, modulation of the CD30 molecule was investigated by the treatment with 12-O-tetradecanoyl-phorbol-13-acetate (TPA). When cultures were supplemented with TPA, CD30 transcript was downregulated in a dose- and time-dependent manner in the erythroleukemia cell line K562. Half reduction of CD30 transcript, precursor protein and surface protein was at 3 h, 6 h, and 40 h, respectively, by Northern blot and Western blot analyses. This consecutive reduction of both the transcript and proteins suggests that TPA directly inhibits the transcriptional step of CD30, and subsequently CD30 molecules would decrease on the cell surface. To determine whether the protein kinase C (PKC) pathway is involved in this reduction, a PKC inhibitor, 10 microM H-7, was added to the K562 culture. The addition of H-7 recovered the inhibitory effect of TPA, indicating that PKC is involved in the transcription of CD30. When either 2 micrograms/ml actinomycin D or 20 micrograms/ml cycloheximide was added simultaneously with TPA to the culture, the repressive effect of TPA on CD30 was abolished. These results showed that the repression would also partly involve ongoing mRNA and protein synthesis under TPA treatment.
Insights
12-O-tetradecanoyl-phorbol-13-acetate (TPA) downregulates CD30 expression in K562 cells. This TPA-induced reduction involves the protein kinase C (PKC) pathway and ongoing mRNA and protein synthesis.
Area of Science:
- Immunology
- Molecular Biology
- Cell Signaling
Background:
- CD30, a receptor superfamily member, has diverse immune functions.
- The precise mechanisms regulating CD30 expression remain largely unelucidated.
- Understanding CD30 regulation is crucial for immune response modulation.
Purpose of the Study:
- To investigate the modulation of CD30 molecule expression.
- To elucidate the signaling pathways involved in CD30 regulation by TPA.
- To determine the role of protein kinase C (PKC) in CD30 transcriptional control.
Main Methods:
- Utilized K562 erythroleukemia cell line.
- Treated cells with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in dose- and time-dependent manners.
- Employed Northern blot and Western blot analyses to quantify CD30 transcript and protein levels.
- Investigated the involvement of the PKC pathway using H-7 inhibitor.
- Assessed the role of mRNA and protein synthesis using actinomycin D and cycloheximide.
Main Results:
- TPA treatment led to a dose- and time-dependent downregulation of CD30 transcript and protein in K562 cells.
- Significant reductions in CD30 transcript, precursor, and surface protein were observed at specific time points.
- Inhibition of PKC with H-7 reversed the TPA-induced downregulation, confirming PKC involvement.
- Simultaneous addition of actinomycin D or cycloheximide abolished TPA's repressive effect, indicating involvement of mRNA and protein synthesis.
Conclusions:
- TPA directly inhibits the transcriptional regulation of CD30.
- The protein kinase C (PKC) pathway plays a critical role in mediating TPA's effect on CD30 transcription.
- Ongoing mRNA and protein synthesis are partially involved in the TPA-mediated repression of CD30 expression.